Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
NCT04822337
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on combining different therapies to see how well they work together. This unique combination aims to improve patient outcomes by targeting the cancer more effectively. Here are some key points about the study:
- The study investigates a combination of therapies that have not been widely used together before.
- It aims to assess how well these therapies can work in tandem to fight the cancer.
- Patients will be monitored closely to evaluate the effectiveness and any side effects of the treatment.
- The study includes various patient demographics to understand how different groups respond to the treatment.
- Researchers hope that this approach will lead to better management of the disease and improve the quality of life for patients.
Third Opinion AI Generated Synopsis
Trial Summary
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
